Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis

Molecular Medicine

Volumn 12, Issue 9-10, 2006, Pages 252-258

  Valentine, Catherine H ^a   Hellman, Judith ^a,b   Beasley Topliffe, Laura K ^a   Bagchi, Aranya ^a   Warren, H Shaw ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LIPID; LIPOPROTEIN; MONOCLONAL ANTIBODY; MUREIN LIPOPROTEIN; MUREIN LIPOPROTEIN ANTIBODY; OUTER MEMBRANE PROTEIN; PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN; PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN ANTIBODY; POLYCLONAL ANTIBODY; TOLL LIKE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MEMBRANE; BACTERIUM MUTANT; BURN; CECUM; CELL ACTIVATION; CONTROLLED STUDY; DISEASE MODEL; ESCHERICHIA COLI; FIBRIN CLOT; GENETIC CONSERVATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; INTESTINE PERFORATION; LIGATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERITONITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PUNCTURE; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BURNS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOBLOTTING; INTERLEUKIN-6; LIPOPROTEINS; MICE; PEPTIDOGLYCAN; PERITONITIS; SEPSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845535170     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00065.Valentine     Document Type: Article

References (47)

1. Chedid L, Parant M, Boyer F. (1968) A proposed mechanism for natural immunity to enterobacterial pathogens. J. Immunol. 100:292-301.
2. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225-30.
3. Braude AI, Douglas H, Davis CE. (1973) Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J. Infect. Dis. 128:3157-64.
4. McCabe WR. (1972) Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J. Immunol. 108:601-10.
5. McCabe WR, Bruins SC, Craven DE, Johns M. (1977) Cross-reactive antigens: Their potential for Immunization-induced immunity to gram-negative bacteria. J. Infect. Dis. 136:3161-6.
6. McCabe WR, Kreger BE, Johns M. (1972) Type-specific and Cross-reactive antibodies in Gram-negative bacteremia. N. Engl. J. Med. 287:261-7.
7. McCabe WR, DeMaria A, Berberich H, Johns MA. (1988) Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re Chemotype) mutant. J. Infect. Dis. 158:291-300.
8. Ziegler EJ, McCutchan JA, Douglas H, Braude AI. (1975) Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Trans. Assoc. Am. Phys. 88:101-8.
9. McCabe WR. (1972) Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J. Immunol. 108:601-10.
10. Johns MA, Skehill A, McCabe WR. (1983) Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J. Infect. Dis. 147:57-67.
11. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. J. Amer. Med. Assoc. 266:1097-102.
12. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al. (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit. Care. Med. 23:994-1006.
13. Ziegler EJ, Fisher CJ, Jr., Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324:429-36.
14. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, Chess Trial Study Group. (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121:1-5.
15. Cross AS. (1994) Antiendotoxin antibodies: A dead end? Ann. Intern. Med. 121:58-9.
16. Warren HS, Amato SF, Fitting C, Black KM, Loiselle PM, Pasternack MS, et al. (1993) Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177:89-97.
17. Heumann D, Baumgartner J-D, Jacot-Guillarmod H, Glauser MP. (1991) Antibodies to core lipopolysaccharide determinants: Absence of cross-reactivity with heterologous lipopolysaccharides. J. Infect. Dis. 163:762-8.
18. Di Padova F, Brade H, Barclay GR, Poxton IR, Liehl E, Schuetze E, et al. (1993) A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect. Immun. 61:3863-72.
19. Hellman J, Zanzot EM, Loiselle PM, Amato SF, Black KM, Ge Y, et al. (1997) Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous Gram-negative bacteria. J. Infect. Dis. 176:1260-8.
20. Hellman J, Loiselle PM, Tehan MM, Allaire JE, Boyle LA, Kurnick JT, et al. (2000) Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum. Infect. Immun. 68:2566-72.
21. Hellman J, Loiselle PM, Zanzot EM, Tehan MM, Boyle LA, Kurnick JT, et al. (2000) Release of Gram-negative outer membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5. J. Infect. Dis. 181:1034-43.
22. Hellman J, Roberts JDJ, Tehan MM, Allaire JE, Warren HS. (2002) Bacterial peptidoglycan-associated lipoprotein is released into the blood-stream in gram-negative sepsis and causes inflammation and death in mice. J. Biol. Chem. 277(16):14274-80.
23. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, et al. (1999) Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 285:736-9.
24. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, et al. (1999) Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274:33419-25.
25. Braun V. (1975) Covalent lipoprotein from the outer membrane of Escherichia coli. Biochim. Biophys. Acta. 415:335-77.
26. Inouye S, Takeishi K, Lee N, DeMarrini M, Hiroshima A, Inouye M. (1976) Lipoprotein from the outer membrane of Escherichia coli: purification, parachrystallization, and some properties of its free form. J. Bacteriology. 127:555.
27. Suzuki H, Nishimura Y, Yasuda S, Nishimura A, Yamada M, Hirota Y. (1978) Murein-lipoprotein of Escherichia coli: a protein involved in the stabilization of bacterial cell envelope. Mol. Gen. Genet. 167:1-9.
28. Hirota N, Suzuki H, Nishimura Y, Yasuda S. (1977) On the process of cellular division in Escherichia coli: A mutant of E. coli lacking a murein-lipoprotein. Proc. Natl. Acad. Sci. 74:1417-20.
29. Mizuno T. (1981) A novel peptidoglycan-associated lipoprotein (PAL) found in the outer membrane of Proteus mirabilis and other gram-negative bacteria. J. Biochem. 89:1039-49.
30. Cascales E, Bernadac A, Gavioli M, Lazzaroni JC, Lloubes R. (2002) Pal lipoprotein of Escherichia coli plays a major role in outer membrane integrity. J. Bacteriol. 184:754-9.
31. Zhang H, Peterson JW, Niesel DW, Klimpel GR. (1997) Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. J. Immunol. 159:4868-78.
32. Liang MD, Bagchi A, Warren HS, Tehan MM, Trigilio JA, Beasley-Topliffe LK, et al. (2005) Bacterial peptidoglycan-associated lipoprotein: a naturally occurring toll-like receptor 2 agonist that is shed into serum and has synergy with lipopolysaccharide. J. Infect. Dis. 191:939-48.
33. Lazzaroni J-C, Portalier R. (1992) The excC gene of Escherichia coli K-12 required for cell envelope integrity encodes the peptidoglycan-associated lipoprotein (PAL). Mol. Microbiol. 6:735-42.
34. Nikaido H. (1994) Isolation of Outer Membranes. Methods of Enzymology. 235:225-34.
35. Siber GR, Kania SA, Warren HS. (1985) Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 152:954-64.
36. Warren HS, Glennon M, de Deckker FA, Tello D. (1991) Role of normal serum in the binding of lipopolysaccharide to IgG fractions from rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 163:1256-66.
37. Ge Y, Ezzell RM, Tompkins RG, Warren HS. (1994) Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J. Infect. Dis. 169:95-104.
38. Zollinger WD, Boslego JW. (1981) A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods. 46:129-40.
39. Wichtermann K, Baus A, Chaudry I. (1980) Sepsis and septic shock - A review of laboratory models and a proposal. J. Surg. Res. 28:189.
40. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. (1999) Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. 67:6603-10.
41. Stevens EJ, Ryan CM, Friedberg JS, Barnhill RL, Yarmush ML, Tompkins RG. (1994) A quantitative model of invasive Pseudomonas infection in burn injury. J. Burn Care Rehab. 15:232-5.
42. Busch NA, Zanzot EM, Loiselle PM, Carter EA, Allaire JE, Yarmush ML, et al. (2000) A model of infected burn wounds using Escherichia coli O18:K1:H7 for the study of gram-negative bacteremia and sepsis. Infect. Immun. 68:3349-51.
43. Ahrenholz DH, Simmons RL. (1980) Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery. 88:41-7.
44. Tate WJ, Douglas HL, Braude AI. (1966) Protection against lethality of E. coli endotoxins with "O" antiserum. ANN NY Acad. Sci. 133:746-62.
45. Chen T-Y, Warren HS, Greene E, Black KM, Frostell CG, Robinson DR, et al. (1993) Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on pulmonary hemodynamics. J. Appl. Physiol. 74:423-7.
46. Kim KS, Kang JH, Cross AS, Kaufman B, Zollinger W, Sadoff J. (1988) Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J. Infect. Dis. 157:47-53.
47. Sha J, Fadl AA, Kumpel GR, Niesel DW, Popov VL, Chopra AK. (2004) The two murein lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism. Infect. Immun. 72:3987-4003.